Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Buy” by Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received an average rating of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $9.50.

A number of analysts recently issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Quince Therapeutics in a research report on Thursday, January 2nd. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Brookline Capital Management started coverage on Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. Finally, Maxim Group initiated coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They set a “buy” rating and a $6.00 price objective on the stock.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $1.59 on Monday. The firm has a market cap of $69.96 million, a price-to-earnings ratio of -1.28 and a beta of 0.64. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average is $1.86 and its two-hundred day moving average is $1.22.

Institutional Investors Weigh In On Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC lifted its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the SEC. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.